Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

A. Frerichs, Kristine; P. M. Verkleij, Christie; Victoria Mateos, Maria; G. Martin, Thomas; Rodriguez, Cesar; Nooka, Ajay; Banerjee, Arnob; Chastain, Katherine; Perales-Puchalt, Alfredo; Stephenson, Tara; Uhlar, Clarissa; Kobos, Rachel; van der Holt, Bronno; Kruyswijk, Sandy; T. Kuipers, Maria; Groen, Kaz; Vishwamitra, Deeksha; Skerget, Sheri; Cortes-Selva, Diana; Doyle, Margaret; L. Zaaijer, Hans; Zweegman, Sonja; I. Verona, Raluca; W. C. J. van de Donk, Niels

doi:10.1182/bloodadvances.2023011658

Public

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Shared by NobleBlocks on Dec 28, 2023 • 12:00 AM UTC

Authors:

Kristine A. Frerichs

Christie P. M. Verkleij

Maria Victoria Mateos

Abstract

Abstract Teclistamab and other B-cell maturation antigen (BCMA)–targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B ce...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!